Skip to content
10-Q

Quarterly Report

Advanced Biomed Inc ADVB

0001213900-26-057226

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2026 · Mar 31, 2026 1.28M sh
Shares Diluted Q3 2026 · Mar 31, 2026 1.15M sh
Shares Diluted restated Q3 2026 · Mar 31, 2025 1.02M sh
Shares Diluted restated Q3 2026 · Mar 31, 2025 1.01M sh
Shares Outstanding Q3 2026 · Mar 31, 2026 1.38M sh
Capex Q3 2026 · Mar 31, 2026 $15.94K
Capex Q3 2026 · Mar 31, 2025 $11.5K
Operating Cash Flow Q3 2026 · Mar 31, 2026 −$1.36M
Operating Cash Flow Q3 2026 · Mar 31, 2025 −$4.28M
Cash And Equivalents Q3 2026 · Mar 31, 2026 $2.6M
Cash And Equivalents Q3 2026 · Jun 30, 2025 $2.87M
Cash And Equivalents restated Q3 2026 · Mar 31, 2025 $3.18M
Stockholders Equity Q3 2026 · Mar 31, 2026 $9.21M
Stockholders Equity Q3 2026 · Jun 30, 2025 $3.48M
Stockholders Equity Q3 2026 · Mar 31, 2025 $4.13M
Stockholders Equity Q3 2026 · Jun 30, 2024 $1.66M
Current Liabilities Q3 2026 · Mar 31, 2026 $1.43M
Current Liabilities Q3 2026 · Jun 30, 2025 $10.09M
Total Liabilities Q3 2026 · Mar 31, 2026 $1.44M
Total Liabilities Q3 2026 · Jun 30, 2025 $10.24M
Current Assets Q3 2026 · Mar 31, 2026 $10.53M
Current Assets Q3 2026 · Jun 30, 2025 $13.24M
Total Assets Q3 2026 · Mar 31, 2026 $10.65M
Total Assets Q3 2026 · Jun 30, 2025 $13.72M
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.38
Eps Diluted Q3 2026 · Mar 31, 2026 $5.21
Eps Diluted restated Q3 2026 · Mar 31, 2025 −$1.35
Eps Diluted restated Q3 2026 · Mar 31, 2025 −$2.54
Eps Basic Q3 2026 · Mar 31, 2026 −$0.38
Eps Basic Q3 2026 · Mar 31, 2026 $5.21
Eps Basic restated Q3 2026 · Mar 31, 2025 −$1.35
Eps Basic restated Q3 2026 · Mar 31, 2025 −$2.54
Sga Expense Q3 2026 · Mar 31, 2026 $276.61K
Sga Expense Q3 2026 · Mar 31, 2026 $646.21K
Sga Expense restated Q3 2026 · Mar 31, 2025 $347.54K
Sga Expense restated Q3 2026 · Mar 31, 2025 $475.09K
Rd Expense Q3 2026 · Mar 31, 2026 $243.23K
Rd Expense Q3 2026 · Mar 31, 2026 $665.14K
Rd Expense restated Q3 2026 · Mar 31, 2025 $219.97K
Rd Expense restated Q3 2026 · Mar 31, 2025 $600.06K
Net Income Q3 2026 · Mar 31, 2026 −$488.94K
Net Income Q3 2026 · Mar 31, 2026 $5.98M
Net Income Q3 2026 · Mar 31, 2025 −$1.38M
Net Income Q3 2026 · Mar 31, 2025 −$2.56M